SolVin and Arkema to separate from VCM and PVC joint ventures

25 June 2010 10:47  [Source: ICIS news]

LONDON (ICIS news)--SolVin and Arkema will separate from their joint ventures in vinyl chloride monomer (VCM) and polyvinyl chloride (PVC) production in France and Spain, the companies said on Friday.

Effective from 1 July 2010, both groups have decided to acquire their reciprocal minority interests within the industrial entities of VinylFos, Vinilis and VinylBerre.

Following this deal, both partners would regain their respective independence on the production sites in which they hold a majority stake, the companies said.

European PVC producer SolVin would become the sole shareholder of Vinilis, based in Spain, and French chemical maker Arkema would become the sole shareholder of VinylFos and VinylBerre in France.

"This operation will enable SolVin to simplify its industrial structure in this part of the European Union", said Enzo Morici, general manager of Solvay's vinyls business unit.

"SolVin always reacts very fast to market changes and customer requests. It will be even more able to do so after this operation," added SolVin managing director, Pierre Tucoulat.

“This streamlining of manufacturing structures will help us enhance our response and serve our customers in Europe more efficiently,” said Otto Takken, Arkema’s executive vice president of vinyl products.

Both companies said the agreement would not impact their workforce or have consequences or on their results.

SolVin is a joint venture of Solvay (75%) and BASF (25%).

($1 = €0.81)

For more on Arkema, Solvay, BASF visit ICIS company intelligence
To discuss issues facing the chemical industry visit ICIS connect

By: Franco Capaldo
+44 (0)20 8652 3214

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly